The UK-based privately owned pharma company focuses on cancer stem cell therapies, with an interest in prostate cancer stem cells.
The account will be headed by director Adam Michael. He said: 'We are working with Pro-Cure to raise its profile within the life-science community, targeting venture financiers and the pharma industry as potential product development partners.'
Abchurch will focus on targeting life science specialist publications such as Scrip and EP Vantage, as well as national broadcast and print media that have a vested interest in science and technology business. Its strategy will involve presenting stories to the media on a semi-exclusive basis and providing advance briefings to the nationals and specialist publications.
Pro-Cure's work is still at research level and is five to ten years away from appearing on the market. 'This is very much a b2b corporate comms programme. At this early stage of development, the subtlety of the PR programme will be to raise significant awareness within the desired target audiences, without sensationalising the story in mainstream media,' said Michael.
Pro-Cure Therapeutics is focused on developing drugs targeted against cancer stem cells.
Pro-Cure's research is not aimed at harvesting and growing stem cells for tissue regeneration therapy. Instead it is characterising and identifying the unique properties of cancer stem cells in order to kill the cell from its root.